SWOG GAP
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
- NCT04871529 ↗
- Terminated
- SWOG Cancer Research Network
- Focused
We haven't built an HCP commentary report on SWOG GAP (avelumab plus gemcitabine plus carboplatin in cisplatin-ineligible muscle-invasive urothelial carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWOG GAP so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8
- Interventions
- Therapeutic Conventional Surgery; Avelumab; Gemcitabine Hydrochloride; Carboplatin
- Arms
- Arm A (avelumab, gemcitabine, carboplatin, surgery) · Experimental
- Arm B (surgery) · Experimental
- Enrollment
- 6
- Primary outcomes
- Pathologic Complete Response
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Aug 10, 2022
- Primary completion
- Nov 14, 2023
- Results posted
- Yes
- Registry record
- NCT04871529 · updated Dec 30, 2024